Drugs that contain Tepotinib Hydrochloride

1. Drug name - TEPMETKO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8921357 EMD SERONO INC Pyridazinone derivatives
May, 2028

(5 years from now)

US8329692 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Oct, 2029

(7 years from now)

US8580781 EMD SERONO INC Pyridazinone derivatives
Mar, 2030

(7 years from now)

CN101687857A EMD SERONO INC Pyrimidinyl Pyridazinone Derivative
Apr, 2028

(5 years from now)

CN101743241B EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

CN101687857B EMD SERONO INC Pyridazinone Derivates
Apr, 2028

(5 years from now)

CN101743241A EMD SERONO INC Pyridazinone Derivates
Apr, 2028

(5 years from now)

IN281477B EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

IN201000482P2 EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

IN201000486P2 EMD SERONO INC Pyrimidinyl-Pyridazinone Derivates
Jul, 2028

(5 years from now)

IN273292B EMD SERONO INC Pyrimidinyl-Pyridazinone Derivatives
Jul, 2028

(5 years from now)

EP2754660A1 EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

EP2164843B1 EMD SERONO INC Pyridazinone Derivates
Apr, 2028

(5 years from now)

EP2164843A1 EMD SERONO INC Pyridazinone Derivates
Apr, 2028

(5 years from now)

EP2754660B1 EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

EP2164844A1 EMD SERONO INC Pyrimidinyl Pyridazinone Derivates
Jul, 2028

(5 years from now)

EP2164844B1 EMD SERONO INC Pyrimidinyl Pyridazinone Derivates
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284300 EMD SERONO INC Pyridazinone derivatives Apr, 2028

(5 years from now)

US9403799 EMD SERONO INC Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase Jul, 2028

(5 years from now)

US8658643 EMD SERONO INC Pyrimidinyl pyridazinone derivatives Jul, 2028

(5 years from now)

US9062029 EMD SERONO INC Pyrimidinyl pyridazinone derivatives Jul, 2028

(5 years from now)

US8927540 EMD SERONO INC Pyridazinone derivatives Jul, 2028

(5 years from now)

Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by administering an effective amount of tepotinib; Treating a solid tumor, including lung cancer, having a met kinase alteration(s) by administering an effective amount of tepotinib

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 225MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.